FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

On November 16, 2026, the Food and Drug Administration approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with giredestrant in combination with everolimus.